These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 11043756)

  • 1. Development of a high-performance liquid chromatographic-mass spectrometric assay for the specific and sensitive quantification of Ro 64-0802, an anti-influenza drug, and its pro-drug, oseltamivir, in human and animal plasma and urine.
    Wiltshire H; Wiltshire B; Citron A; Clarke T; Serpe C; Gray D; Herron W
    J Chromatogr B Biomed Sci Appl; 2000 Aug; 745(2):373-88. PubMed ID: 11043756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies.
    Hill G; Cihlar T; Oo C; Ho ES; Prior K; Wiltshire H; Barrett J; Liu B; Ward P
    Drug Metab Dispos; 2002 Jan; 30(1):13-9. PubMed ID: 11744606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biodistribution and metabolism of the anti-influenza drug [11C]oseltamivir and its active metabolite [11C]Ro 64-0802 in mice.
    Hatori A; Arai T; Yanamoto K; Yamasaki T; Kawamura K; Yui J; Konno F; Nakao R; Suzuki K; Zhang MR
    Nucl Med Biol; 2009 Jan; 36(1):47-55. PubMed ID: 19181268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of pharmacokinetic interaction between the oral anti-influenza neuraminidase inhibitor prodrug oseltamivir and antacids.
    Snell P; Oo C; Dorr A; Barrett J
    Br J Clin Pharmacol; 2002 Oct; 54(4):372-7. PubMed ID: 12392584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of milk on the pharmacokinetics of oseltamivir in healthy volunteers.
    Morimoto K; Kishimura K; Nagami T; Kodama N; Ogama Y; Yokoyama M; Toda S; Chiyoda T; Shimada R; Inano A; Kano T; Tamai I; Ogihara T
    J Pharm Sci; 2011 Sep; 100(9):3854-61. PubMed ID: 21607954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative determination of oseltamivir and oseltamivir carboxylate in human fluoride EDTA plasma including the ex vivo stability using high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.
    Kromdijk W; Rosing H; van den Broek MP; Beijnen JH; Huitema AD
    J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Apr; 891-892():57-63. PubMed ID: 22418071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802.
    He G; Massarella J; Ward P
    Clin Pharmacokinet; 1999 Dec; 37(6):471-84. PubMed ID: 10628898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and dosage recommendations for an oseltamivir oral suspension for the treatment of influenza in children.
    Oo C; Barrett J; Hill G; Mann J; Dorr A; Dutkowski R; Ward P
    Paediatr Drugs; 2001; 3(3):229-36. PubMed ID: 11310719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and in vivo stability of oseltamivir within a bioequivalence trial.
    Grigoriev A; Borisova I; Yaroshenko I; Sidorova A
    Anal Bioanal Chem; 2016 May; 408(14):3891-7. PubMed ID: 27002612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Column-switching high-performance liquid chromatography combined with ionspray tandem mass spectrometry for the simultaneous determination of the platelet inhibitor Ro 44-3888 and its pro-drug and precursor metabolite in plasma.
    Zell M; Husser C; Hopfgartner G
    J Mass Spectrom; 1997 Jan; 32(1):23-32. PubMed ID: 9008866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and validation of a liquid chromatographic-tandem mass spectrometric method for determination of oseltamivir and its metabolite oseltamivir carboxylate in plasma, saliva and urine.
    Lindegårdh N; Hanpithakpong W; Wattanagoon Y; Singhasivanon P; White NJ; Day NP
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Nov; 859(1):74-83. PubMed ID: 17913596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. P-glycoprotein restricts the penetration of oseltamivir across the blood-brain barrier.
    Ose A; Kusuhara H; Yamatsugu K; Kanai M; Shibasaki M; Fujita T; Yamamoto A; Sugiyama Y
    Drug Metab Dispos; 2008 Feb; 36(2):427-34. PubMed ID: 18039806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolism of the influenza neuraminidase inhibitor prodrug oseltamivir in the rat.
    Sweeny DJ; Lynch G; Bidgood AM; Lew W; Wang KY; Cundy KC
    Drug Metab Dispos; 2000 Jul; 28(7):737-41. PubMed ID: 10859145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic Modeling and Monte Carlo Simulation to Predict Interindividual Variability in Human Exposure to Oseltamivir and Its Active Metabolite, Ro 64-0802.
    Ito M; Kusuhara H; Ose A; Kondo T; Tanabe K; Nakayama H; Horita S; Fujita T; Sugiyama Y
    AAPS J; 2017 Jan; 19(1):286-297. PubMed ID: 27800573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of oseltamivir carboxylic acid in human serum by solid phase extraction and high performance liquid chromatography with UV detection.
    Bahrami G; Mohammadi B; Kiani A
    J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Mar; 864(1-2):38-42. PubMed ID: 18313995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Developmental changes of brain distribution and localization of oseltamivir and its active metabolite Ro 64-0802 in rats.
    Morimoto K; Nagami T; Matsumoto N; Wada S; Kano T; Kakinuma C; Ogihara T
    J Toxicol Sci; 2012; 37(6):1217-23. PubMed ID: 23208436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiosyntheses of two positron emission tomography probes: [11C]Oseltamivir and its active metabolite [11C]Ro 64-0802.
    Konno F; Arai T; Zhang MR; Hatori A; Yanamoto K; Ogawa M; Ito G; Odawara C; Yamasaki T; Kato K; Suzuki K
    Bioorg Med Chem Lett; 2008 Feb; 18(4):1260-3. PubMed ID: 18226899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1-5 years.
    Oo C; Hill G; Dorr A; Liu B; Boellner S; Ward P
    Eur J Clin Pharmacol; 2003 Sep; 59(5-6):411-5. PubMed ID: 12910331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-performance liquid chromatographic determination of GS4071, a potent inhibitor of influenza neuraminidase, in plasma by precolumn fluorescence derivatization with naphthalenedialdehyde.
    Eisenberg EJ; Cundy KC
    J Chromatogr B Biomed Sci Appl; 1998 Sep; 716(1-2):267-73. PubMed ID: 9824240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oseltamivir: a review of its use in influenza.
    McClellan K; Perry CM
    Drugs; 2001; 61(2):263-83. PubMed ID: 11270942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.